Juvenescence Limited is focused on enabling therapies to increase healthy human longevity. The team at Juvenescence believes that recent advances in science have greatly improved our understanding of the biology of aging and seeks to develop therapeutics with the possibility of slowing, halting or potentially reversing elements of aging. Juvenescence will create or invest in new companies with aging or age-related therapeutics, in-license compounds from academia or industry, or engage in joint ventures to develop therapeutics for longevity.

The company was founded in 2017 by Jim Mellon, Dr. Greg Bailey, Dr. Declan Doogan, Anthony Chow, and Alexander Pickett. The Juvenescence team members are highly experienced drug developers, entrepreneurs and investors with a significant history of success in the life sciences.